Patents Assigned to Probiodrug
  • Raising blood sugar level in hypoglycemic mammals by administering inhibitors of dipeptidyl peptidase IV
    Patent number: 6319893
    Abstract: A method of raising the blood sugar level in a mammal having hypoglycemia is described. The method reduces degradation of glucagon by administering to the mammal a therapeutically effective amount of an inhibitor of dipeptidyl peptidase IV and physiologically acceptable adjuvants and/or excipients.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: November 20, 2001
    Assignee: Probiodrug
    Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Kerstin Kuhn-Wache, Fred Rosche
  • Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
    Patent number: 6303661
    Abstract: Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
    Type: Grant
    Filed: October 6, 1998
    Date of Patent: October 16, 2001
    Assignee: Probiodrug
    Inventors: Hans-Ulrich Demuth, Fred Rosche, Joem Schmidt, Robert P. Pauly, Christopher H. S. McIntosh, Ray A. Pederson